ITMCTR2100004818招募中未知
To investigate the clinical effect and ctDNA dynamic change of 'Jianpi Lishi Huayu Decoction' on the 'maximum androgen blocking' of advanced prostate cancer
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 85（—）
- 性别
- Male
入选标准
- •1. Male, in line with the Western medical diagnostic criteria of Diagnostic Criterion for Prostate Cancer, confirmed as prostate cancer by biopsy and puncture, and not complicated with neuroendocrinization, signet ring cell or small cell characteristics;
- •2. Meet the American Joint Committee on Cancer (AJCC) 8th edition TNM staging criteria for prostate cancer, which are T3-4, N0-1, M0-1;
- •3. Diagnostic criteria of traditional Chinese medicine: with reference to the teaching material of TCM oncology (dai-han zhou editor, guangzhou higher education press, 2007) and the standard of China association of Chinese medicine tumor diagnosis and treatment of traditional Chinese medicine guide (2008) and the malignant tumor diagnosis and treatment of traditional Chinese medicine guide (hong-sheng Lin editor, people's medical publishing house, 2014), the state bureau of technical supervision issued term in the clinical diagnosis and treatment of TCM syndrome part (1997).
- •4. No previous endocrine therapy related to prostate cancer;
- •5. According to Zubrod-Ecog-WHO (ZPS, 5-point method) scoring criteria, the baseline assessment of patients before enrolment should meet 0-2 points;
- •6. Bone marrow hematopoietic function was not significantly impaired (WBC >= 3.5 x 10^9/L, platelet >= 100 x 10^9/L, hemoglobin >= 90g/L);
- •7. Biochemical examination shall meet the following standards:
- •1) TBIL < 1.5 x ULN;
- •2) ALT and AST < 2 ULN (<= 5 x ULN if abnormal liver function is caused by liver metastasis);
- •3) Serum Cr acuities were 1.25 x ULN or endogenous creatinine clearance > 45 ml/min (Cockcroft - Gault formula);
- •4) Coagulation function should meet the following criteria: INR <= 1.5 and APTT <= 1.5 x ULN;
- •8. The expected survival time is not less than 12 weeks;
- •9. Patients volunteered to participate in this study with good compliance, can cooperate with treatment and observation, and sign informed consent form (ICF).
排除标准
- •1. Combined with serious primary diseases of the heart, brain, liver and hematopoietic system or with other cancers;
- •2. Combined with renal injury due to spinal cord compression or urinary tract obstruction, or who are at risk of developing this phenomenon;
- •3. Allergic to carlutamine or any component of the preparation;Have a history of allergy to goserrelin acetate/leproterreli;
- •4. Combined with central nervous system disorders or mental disorders, with a clear history of previous neurological or mental disorders, including epilepsy or dementia;
- •5. Factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction);
- •6. Participated in other clinical trials within the last 3 months;n acetate preparation ingredients, synthetic LH-RH or LH-RH derivatives;
- •7. The Investigator believes that there is any condition that may harm the subject or cause the subject to fail to meet or perform the study requirements;
- •8. Increases the risk of participating in the study or of the study drug and, in the investigator's judgment, may result in a serious disease or non-tumor comorbidity that would ineligible the patient for inclusion in the study;
- •9. Failed to comply with the protocol;
- •10. Unsuitable for inclusion by attending physicians.
研究者
相似试验
招募中
不适用
To investigate the clinical effect and ctDNA dynamic change of 'Jianpi-Lishi-Huayu Decoction' on the 'maximum androgen blocking' of advanced prostate cancerProstate cancerITMCTR2100004504The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
招募中
不适用
Clinical efficacy of ctDNA dynamics before and after total neoadjuvant treatment in locally adjuvant rectal cancer.KCT0008155Chonnam National University Hospital Hwasun Hospital45
已完成
不适用
Prospective study evaluating ctDNA as a biomarker for treatment response in head and neck squamous cell carcinoma*NL-OMON46578Antoni van Leeuwenhoek Ziekenhuis70
进行中（未招募）
不适用
CLINICAL ACTIVITY OF DNA DAMAGING AND NON-DAMAGING CHEMIOTHERAPY REGIMENS IN ADVANCED BREAST CANCER PATIENTS WITH DIFFERENT BIOLOGICAL SUB-TYPES DEFINED BY BIOMARKERS EVALUATION ON CIRCULATING TUMOR CELLS - CTC PLATINUMMedDRA version: 9.1Level: SOCClassification code 10038604METASTATIC BREAST CANCEREUCTR2009-012738-65-ITAZIENDA USL 4 PRATO
Unknown
3 期
Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal CancerRectal Cancer, AdenocarcinomaNeoadjuvant ChemoradiationNCT03038217Peking Union Medical College Hospital300